ABBOTT LABORATORIES (ABT) Company Report

The FDA approved Abbott’s over-the-wire Volt Pulsed Field Ablation (PFA) System for treating atrial fibrillation after its CE mark in March, with U.S. commercial cases set to begin soon.
The pivotal VOLT-AF IDE trial enrolled 392 patients across 40 centers in the U.S., Europe, Canada and Australia, meeting key safety and effectiveness endpoints for both paroxysmal and persistent AFib.
Volt integrates with Abbott’s EnSite X mapping platform and uses a balloon-in-basket catheter to map, pace and ablate in one device, enabling procedures under conscious sedation.
CEO Robert Ford said Abbott’s electrophysiology segment is experiencing double-digit growth, and he expects Volt to be a major growth driver for the cardiology business in 2026.

3 days ago

Morningstar

Abbott receives FDA approval for Volt PFA System to treat AFib

ABT

Product Launch

Abbott’s Volt PFA System has received FDA approval for treating atrial fibrillation in the U.S., with commercial cases to begin soon.
Approval is based on the VOLT-AF IDE study of 392 patients at 40 centers, demonstrating strong safety and effectiveness in both paroxysmal and persistent AFib.
The all-in-one system features real-time contact visualization, shorter procedure times, conscious sedation options, reduced radiation exposure and integration with the EnSite™ X EP System.

3 days ago

Press Release

Abbott receives FDA clearance and CE Mark for Amplatzer Piccolo Delivery System

ABT

Product Launch

Abbott has received FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, designed to treat premature infants with patent ductus arteriosus (PDA).
The new delivery system, intended for use with Abbott’s Amplatzer Piccolo Occluder, allows the implant to be performed with a single catheter and more precise device positioning in tiny patients.
A PDA requiring treatment affects approximately 20% of premature infants, indicating a significant potential market for the therapy.
This launch complements Abbott’s existing pediatric heart device portfolio, which includes the world’s smallest mechanical heart valve and the HeartMate 3 heart pump for pediatric patients.

7 days ago

Press Release

Abbott announces acquisition of Exact Sciences

ABT

M&A

Abbott will acquire Exact Sciences for $105 per share in cash, representing an equity value of $21 billion and an enterprise value of ~$23 billion.
The transaction is expected to close in 2Q 2026, subject to customary closing conditions and regulatory approvals.
The deal is projected to generate at least $100 million in annual pre-tax synergies by 2028 and to boost Abbott’s organic sales growth by ~50 bps and its Diagnostics segment growth by ~300 bps.
It will be dilutive to adjusted EPS through 2027 (–$0.20 in 2026; –$0.16 in 2027), with accretion resuming in 2028.
Financing will combine cash on hand and debt, targeting an initial adjusted gross debt/EBITDA ratio of ~2.7x while maintaining an investment-grade rating.

Nov 20, 2025, 2:00 PM

Presentation

Abbott acquires Exact Sciences for $21B

ABT

M&A

Abbott will acquire all outstanding shares of Exact Sciences at $105 per share, representing a $21 billion equity and $23 billion enterprise value, with closing expected in Q2 2026.
Exact Sciences is projected to generate > $3 billion in revenue this year, at high-teens organic growth and > 70% adjusted gross margin, and the deal doubles Abbott’s diagnostics TAM from $60 billion to > $120 billion.
The acquisition is expected to add 50 bps to Abbott’s total sales growth, 300 bps to diagnostics growth, and increase adjusted gross margins by 100 bps company-wide and 700 bps in diagnostics, with ≥ $100 million of annual pre-tax synergies by 2028.
Financing will use cash and debt, with pro forma adjusted gross debt/EBITDA of ~2.7x, and EPS impact of – $0.20 in 2026 and – $0.16 in 2027 before turning accretive, targeting double-digit EPS growth by 2027.
The acquisition expands Abbott’s diagnostics leadership in oncology by adding Exact’s cancer portfolio—Cologuard, CancerGuard, Oncotype DX, Oncodetect, and RiskGuard—leveraging Abbott’s global scale.

Nov 20, 2025, 2:00 PM

Transcript

Abbott to acquire Exact Sciences for $21 billion

ABT

M&A

Abbott has entered into a definitive agreement to acquire Exact Sciences at $105 per share, representing a total equity value of $21 billion and an enterprise value of $23 billion, with the transaction expected to close in Q2 2026 subject to customary approvals.
Exact Sciences is projected to generate over $3 billion in revenue in 2025, with a high-teens organic sales growth rate and an adjusted gross margin above 70%, and the deal is expected to double Abbott’s diagnostics TAM from about $60 billion to over $120 billion.
The acquisition is forecast to add 50 bps to Abbott’s total company sales growth and 300 bps to its diagnostics segment growth, and to improve Abbott’s adjusted gross margin by 100 bps (and the diagnostics segment by 700 bps), with at least $100 million in annual pre-tax synergies by 2028.
The deal will be financed with cash on hand and debt, resulting in a pro forma adjusted gross debt/EBITDA of about 2.7× post-close; it is expected to dilute adjusted EPS by $0.20 in 2026 and $0.16 in 2027, turning accretive thereafter with a return to double-digit EPS growth in 2027, while maintaining Abbott’s dividend policy.

Nov 20, 2025, 2:00 PM

Transcript

Abbott to acquire Exact Sciences for $21 billion

ABT

M&A

Abbott entered a definitive agreement to acquire Exact Sciences at $105 per share, implying an equity value of $21 billion and an enterprise value of $23 billion.
Transaction expected to close in Q2 2026, subject to customary closing conditions and regulatory approvals.
Deal projected to add 50 bps to Abbott’s total sales growth, 300 bps to diagnostics growth, and increase adjusted gross margin by 100 bps company-wide and 700 bps in diagnostics.
Anticipates $100 million in annual pre-tax synergies by 2028, financed with cash and debt for a pro forma net debt/EBITDA of 2.7×, with EPS dilution of $0.20 in 2026 and $0.16 in 2027, accretive thereafter.

Nov 20, 2025, 2:00 PM

Transcript

Abbott to acquire cancer diagnostics leader Exact Sciences

ABT

M&A

Abbott will acquire Exact Sciences for $105 per share in cash, implying a $21 billion equity value and a $23 billion enterprise value.
The deal broadens Abbott’s footprint in cancer screening and precision oncology, adding flagship tests like Cologuard and Oncotype DX, and is expected to be immediately accretive to both revenue growth and gross margin.
Exact Sciences is projected to generate over $3 billion in revenue in 2025 with high-teens organic growth, and upon closing Abbott’s diagnostics sales will exceed $12 billion annually.
The transaction, unanimously approved by both boards, is set to close in Q2 2026, subject to shareholder and regulatory approvals, and will be financed with cash and debt with Abbott maintaining an investment-grade rating.

Nov 20, 2025, 12:37 PM

8-K

Abbott to acquire Exact Sciences

ABT

M&A

Abbott to acquire Exact Sciences for $105 per share in cash, implying $21 billion equity value and $23 billion enterprise value (including $1.8 billion net debt).
The deal, expected to close in Q2 2026, is subject to Exact Sciences’ shareholder and regulatory approvals.
Acquisition will be immediately accretive to Abbott’s revenue growth and gross margin, adding leadership in the $60 billion U.S. cancer screening and precision oncology diagnostics segments.
Exact Sciences is projected to generate >$3 billion in revenue this year with high-teens organic growth, and will boost Abbott’s annual diagnostics sales to >$12 billion.

Nov 20, 2025, 12:30 PM

Press Release

Abbott Laboratories in talks to acquire Exact Sciences

ABT

M&A

Abbott is in advanced talks to acquire Exact Sciences, which would add about $3 billion in revenue and expand its diagnostics business
Exact Sciences raised its 2025 revenue guidance to $3.235 billion and reported a Non-GAAP EPS of $0.24 on $851 million in revenue, beating estimates
The potential deal, valued at approximately $20 billion enterprise value with $600–700 million in synergies, is projected to be EPS neutral over three years

Nov 19, 2025, 11:03 PM

Bloomberg

Earnings Transcripts

Quarterly earnings call transcripts for ABBOTT LABORATORIES.

Q3 2025

Oct 15, 2025

→

Q2 2025

Jul 17, 2025

→

Q1 2025

Apr 16, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Robert Ford say about margins?What are ABBOTT LABORATORIES's strategic priorities?How is ABBOTT LABORATORIES positioned vs competitors?How did ABBOTT LABORATORIES do last quarter?

ABBOTT LABORATORIES (ABT)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Robert Ford

Daniel Salvadori

Hubert Allen

Lisa Earnhardt

Philip Boudreau

Board Members

Claire Babineaux-Fontenot

Daniel Starks

Darren McDew

John Stratton

Michael O’Grady

Michael Roman

Michelle Kumbier

Nancy McKinstry

Paola Gonzalez

Robert Alpern

Sally Blount

Analyst Coverage

David Roman

Joshua Jennings

Vijay Kumar

Joanne Wuensch

Travis Steed

Danielle Antalffy

Larry Biegelsen

Robert Marcus

Marie Thibault

Matthew Miksic

Robbie Marcus

Suraj Kalia

Adam Maeder

Danielle Joy Antalffy

Lawrence Biegelsen

Lawrence H. Biegelsen

Matt Miksic

Travis Lee Steed

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent